Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.

Wenying YangXiaohui GuoFelipe LauandLingyu LiHexin FangQin DuLei Kang

Published in: Diabetes, obesity & metabolism (2024)

iGlarLixi showed consistent efficacy and safety across all age and disease duration subgroups in Asian people with uncontrolled T2D, including older individuals and those with longstanding disease.

Keyphrases

physical activity
transcription factor
lymph node metastasis
community dwelling